Patient P-01737
Therapy response 42 at the day-84 endpoint (observed).
Responding: response probability 43%, therapy response 42 today; biology is not blocking the drug.
Drift detected on day 49 (HRV −6 ms, gi toxicity +11, inflammatory load +15); the side effect would have been reported on day 59 — 10 days of warning.
5 of 9 scheduled doses in the last 60 days are biologically confirmed (56%). Dose signature: resting HR +4 bpm, HRV −11 ms.
81% of 284 similar trajectories improved after GI-04; if this one does, discontinuation risk is expected to fall from 95% to ~59%. Keeping fat low is worth 5.6 GI points a day on its own. Losing this patient costs €57k; the intervention costs €180.
- 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- ✓Track each bowel movement today: time, stool form, urgency, overnight waking
- ✓A 15-minute walk after lunch
- 💊Take the scheduled dose as agreed with your care team
- 💊Electrolyte solution, one sachet after any loose stool
Dose is being missed; nothing else works until this is fixed.
GI burden above 65 for 3 days within the onset window
P-01737 is on day 110 of NBL-101 (EC-03, baseline S14): response unstable, tolerance unstable, GI stable. Over 14 days response moved -2 and GI -3; discontinuation risk is 95%. The state is in the failing basin, heading towards failing, after diverging from the model on day 49.
Biology sets the gain: Poor metabolizer, Baseline state S14, Cluster EC-03 (high response / high intolerance), Adherence < 60%; butyrate capacity 42/100, diversity 3.1. Pushing it down: Escherichia coli 28.575% (LPS load) (-34.5), Low butyrate capacity (-27.1), Dietary fat load (-20.6). From the daily log: fat +5.6 GI next day.
Past actions: SC-12 on day 48 → declined.
Next: GI-04 — 81% of 284 similar trajectories improved, 90% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 NBL-101 started — Baseline state S14
- Day 48 SC-12 recommended — Supportive Compound SC-12
- Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 49 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 49.
- Toxicity+11
- Nutritional resilience+8
- Treatment adherence-5
- GI instability-3
What helped?
- Supportive Compound SC-12Day 48Declined by patient
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 8 days
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards failing · 21 from the failing basin, 67 from restoration.
- Keep fat lowGI +5.6 next day on high-intake days · n 27
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+5.6detractor · 95%
- Insoluble fibre+2.3no signal · 53%
- Alcohol+2no signal · 46%
- Histamine load-0.5no signal · 15%
- Simple carbohydrates-0.3no signal · 15%
- Spicy / capsaicin+0.2no signal · 15%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 4 opportunists above range: Escherichia coli, Enterococcus faecium, Streptococcus gallolyticus
- 5 keystone species absent
- Shannon 2 (expected ≥ 3)
- 9 resistance genes
- Host DNA fragmentation atypical
- Tissue recycling index 61
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 42/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 80 bpm
- Wearable1,924 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 57 and rising
- WearableSleep 5.8 h, below personal baseline
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- WearableHRV 26 ms, trending down
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 58
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
- HRV
- 27 ms
- Sleep
- 6.2 h
- Steps
- 1,853
- Resting HR
- 78 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.